Literature DB >> 11329136

Increased expression of cFLIP(L) in colonic adenocarcinoma.

B K Ryu1, M G Lee, S G Chi, Y W Kim, J H Park.   

Abstract

During tumour progression, cancer cells use diverse mechanisms to escape from apoptosis-inducing stimuli, which may include receptor internalization, inhibition of signal pathways, and regulation of specific sets of genes. Substantial numbers of colon cancer cells have been observed to express Fas/Fas ligand, but are resistant to Fas-mediated apoptosis, suggesting that colonic tumours might develop specific mechanisms to overcome Fas-mediated apoptosis. Recently, cellular FLICE-like inhibitory protein (cFLIP) has been identified as an endogenous inhibitor of Fas- or other receptor-mediated apoptosis and its altered high expression has a suspected association with tumour development or progression. In an effort to investigate the prevalence of cFLIP(L) alterations in colon carcinomas and their possible implications for the progression of colon cancers, cFLIP(L) expression was analysed in adenocarcinomas and adenomatous polyps of colon, with matched normal tissues, at RNA and protein levels, by semi-quantitative reverse transcription-polymerase chain reaction (RT-PCR) and immunohistochemistry. cFLIP(L) transcripts were constitutively expressed in colon cancers and expression levels were significantly higher in carcinomas than in normal tissues (p<0.05). Overexpression of cFLIP(L) protein was found exclusively in carcinoma cells in all matched sets analysed and approximately three-fold induction was detected in cancer cells (p<0.05). The expression of cFLIP(L) protein was not significantly altered in adenomatous polyps compared with normal tissues. Taken together, these results strongly suggest that abnormal overexpression of cFLIP(L) is a frequent event in colon carcinomas and might contribute to in vivo tumour transformation. Copyright 2001 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11329136     DOI: 10.1002/path.835

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  28 in total

1.  S-Adenosylmethionine and methylthioadenosine inhibit cellular FLICE inhibitory protein expression and induce apoptosis in colon cancer cells.

Authors:  Tony W H Li; Qingsong Zhang; Pilsoo Oh; Meng Xia; Hui Chen; Sean Bemanian; Natalie Lastra; Magda Circ; Mary Pat Moyer; José M Mato; Tak Yee Aw; Shelly C Lu
Journal:  Mol Pharmacol       Date:  2009-04-16       Impact factor: 4.436

Review 2.  Regulation of chemoresistance via alternative messenger RNA splicing.

Authors:  Scott T Eblen
Journal:  Biochem Pharmacol       Date:  2012-01-08       Impact factor: 5.858

3.  Prognostic significance of TRAIL signaling molecules in stage II and III colorectal cancer.

Authors:  Donal P McLornan; Helen L Barrett; Robert Cummins; Ultan McDermott; Cliona McDowell; Susie J Conlon; Victoria M Coyle; Sandra Van Schaeybroeck; Richard Wilson; Elaine W Kay; Daniel B Longley; Patrick G Johnston
Journal:  Clin Cancer Res       Date:  2010-06-22       Impact factor: 12.531

4.  Expression of c-FLIP in pulmonary metastases in osteosarcoma patients and human xenografts.

Authors:  Krithi Rao-Bindal; Chethan K Rao; Ling Yu; Eugenie S Kleinerman
Journal:  Pediatr Blood Cancer       Date:  2012-12-19       Impact factor: 3.167

Review 5.  Immune-epithelial crosstalk at the intestinal surface.

Authors:  Nadine Wittkopf; Markus F Neurath; Christoph Becker
Journal:  J Gastroenterol       Date:  2014-01-28       Impact factor: 7.527

6.  Pro-apoptotic function of HBV X protein is mediated by interaction with c-FLIP and enhancement of death-inducing signal.

Authors:  Kyun-Hwan Kim; Baik L Seong
Journal:  EMBO J       Date:  2003-05-01       Impact factor: 11.598

Review 7.  Cellular FLICE-inhibitory protein: an attractive therapeutic target?

Authors:  Olivier Micheau
Journal:  Expert Opin Ther Targets       Date:  2003-08       Impact factor: 6.902

8.  Overexpression of cFLIP in head and neck squamous cell carcinoma and its clinicopathologic correlations.

Authors:  Xiuguo Li; Xinliang Pan; Hui Zhang; Dapeng Lei; Dayu Liu; Fenglei Xu; Xinyong Luan
Journal:  J Cancer Res Clin Oncol       Date:  2007-10-09       Impact factor: 4.553

Review 9.  FLIP as an anti-cancer therapeutic target.

Authors:  Jin Kuk Yang
Journal:  Yonsei Med J       Date:  2008-02-29       Impact factor: 2.759

10.  TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.

Authors:  Josep Maria Lluis; Ulrich Nachbur; Wendy Diane Cook; Ian Edward Gentle; Donia Moujalled; Maryline Moulin; Wendy Wei-Lynn Wong; Nufail Khan; Diep Chau; Bernard Andrew Callus; James Edward Vince; John Silke; David Lawrence Vaux
Journal:  PLoS One       Date:  2010-01-08       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.